Blog

Hybridoma technology pioneered monoclonal antibody production. Biointron reviews the process and its ongoing relevance in antibody discovery and development.

VHH antibodies, or sdAbs, combine stability and specificity. Biointron explores their camelid origin and their growing role in biotech and medicine.

Antibody fragmentation generates Fab, F(ab’)2, and scFv. Biointron shows how fragments expand antibody applications in imaging, diagnostics, and therapeutics.

Antibody drug development has revolutionized biomedicine. Biointron highlights stages from discovery to approval that shape antibody-based therapies.

Antibody characterization confirms quality and function. Biointron offers assays to assess purity, stability, and binding for reliable therapeutic development.

Heavy and light chain pairing ensures antigen recognition. Biointron explains its importance in antibody structure, function, and therapeutic application.

Single-cell antibody sequencing reveals repertoire diversity. Biointron applies this method to uncover potent candidates for therapeutic antibody programs.

Anti-mouse antibodies remain vital research tools. Biointron delivers reliable anti-mouse antibodies that support validation and consistent experimental results.

Learn about VHH libraries, including their creation, screening methods, structural diversity, and how nanobody technology supports research, diagnostics, and therapeutics.

High-throughput antibody expression drives speed and scale. Biointron applies automated platforms to deliver reproducible antibodies for research and therapy.

Antibody therapeutics power modern medicine. Biointron reviews monoclonals, bispecifics, and next-gen formats advancing treatment across multiple diseases.

Affinity maturation enhances antibody binding strength. Biointron explains in vivo and in vitro approaches that optimize therapeutic potential and performance with AI and NGS technologies.